
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
One new program helps independents buy or sell a pharmacy.
At its annual trade show in Las Vegas this week, McKesson Corp., which is celebrating its 175th anniversary this year, announced several new programs:





